RE:RE:CC transcriptWith the Delta variant doing its best to cast doubt on any forward looking guidance, Todd's response is intentionally measured. This is understandable given the situation in Louisiana.
The pandemic has been both a boon and a bust for Viemed. While VMD did remarkably well pivoting to vent sales last year, the pandemic interfered with the quarterly growth starting 2020 Q1. In the longer term, the pandemic has likely changed the landscape for future treatment of COPD in favour of VMD's model.
The quarterly CC was less than what I had hoped for. But it was better than some of the fears especially that RT recruitment would be a problem. I am sure that other institutions will start bleeding RTs and that might further drive the adoption of the VMD model.
The pristine balance sheet and cash war chest is certainly nice to have. The fact that cash increased, debts decreased and growth continues all bodes well.
I will be curious if earnings expectations amongst analysts will start to creep up. I thought analyst expectations for Q2 were too low and VMD barely exceeded it by a penny or two. Not all analysts showed up. I chose not to listen live but rather wait for the transcript.
Trading volume was unusually low for CC day. It suggests that funds are yawning at the results. It will only take one fund to make a move to drive share price up or down. Perhaps some will engage in some dollar-cost averaging before Sept 30 when they must report their holdings.
I was disappointed the shameful Phantom Share calculation did not trigger a larger reversal given the share price. The Phantom Share plan has probably knocked off a dollar from the share price.
The comments about looking at acquisitions in a different health care focus is news to me. Perhaps they have a target in mind for them to mention that voluntarily. I am unable to read between the lines on that comment.
All eyes must be on the pandemic between now and next quarter. I doubt anyone will have a major announcement until the pandemic settles down.